GOVX - GeoVax Labs, Inc.
| Previous Close | 0.1990 |
| Open | 0.1990 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.1894 - 0.2015 |
| 52 Week Range | 0.1152 - 9,500.0000 |
| Volume | 238,846 |
| Avg. Volume | 110,073 |
| Market Cap | 2.758M |
| Beta (5Y Monthly) | 1.07 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -39.2480 |
| Earnings Date | Mar 24, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.56 |
- GlobeNewswire
GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update
ATLANTA, GA, March 25, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announced its financial results for the year ended December 31, 2019 and provided an update on its corporate development progress. This was combined with tough capital restructuring decisions that, while painful at the time, have now resulted in GeoVax being better positioned for future financing efforts in support of our programs and increasing shareholder value.
- GlobeNewswire
GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program
ATLANTA, GA, March 18, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today provided an update on its development of a vaccine for prevention/control of novel coronavirus disease (COVID-19) caused by SARS-Cov-2 coronavirus. GeoVax is using its GV-MVA-VLPTM vaccine platform and expertise to design and construct vaccine candidates using genetic sequences from the virus responsible for the ongoing COVID-19 outbreak originating in Wuhan, China.
- GlobeNewswire
GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program
ATLANTA, GA, March 04, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today provided an update on its development of a vaccine for prevention/control of novel coronavirus disease (COVID-19) caused by SARS-Cov-2 coronavirus. The update was given by GeoVax’s Chief Scientific Officer, Farshad Guirakhoo, PhD, during his presentation on emerging infectious diseases entitled “Development of Single Dose Vaccines for Emerging Infectious Diseases Using a Novel MVA Platform” at the World Immunotherapy Congress in San Diego, California.
- GlobeNewswire
GeoVax to Present at World Immunotherapy Congress 2020
ATLANTA, GA, Feb. 27, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, announced today that its Chief Scientific Officer, Farshad Guirakhoo, PhD, will be a featured speaker at the World Immunotherapy Congress, being held March 2-4, 2020 in San Diego, California. The first, on March 2, is entitled Utilizing a Live Modified Vaccinia Ankara Virus to Deliver Tumor Associated Antigen MUC1 on the Surface of Virus Like Particles and will focus on GeoVax’s efforts toward development of cancer immunotherapies. During his second presentation on March 4, entitled Development of Single Dose Vaccines for Emerging Infectious Diseases Using a Novel MVA Platform, Dr. Guirakhoo will discuss the Company’s design of MVA-VLP and non-VLP vaccines for Zika, Ebola, Marburg and Lassa fever vaccines, as well as results from efficacy studies in animal challenge models.
- GlobeNewswire
Update: GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial
ATLANTA, GA, Feb. 06, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (GOVX) (GOVXD), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today commented on the recent discontinuance of the HVTN 702 clinical trial. On February 3, 2020, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), announced that it has stopped administration of vaccinations in its HVTN 702 clinical trial of an investigational HIV vaccine.
- GlobeNewswire
GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial
ATLANTA, GA, Feb. 06, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today commented on the recent discontinuance of the HVTN 702 clinical trial. On February 3, 2020, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), announced that it has stopped administration of vaccinations in its HVTN 702 clinical trial of an investigational HIV vaccine.
- GlobeNewswire
GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine
ATLANTA, GA, and WUHAN, CHINA, Jan. 27, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (GOVXD), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, together with BravoVax, a vaccine developer in Wuhan, China, today announced the signing of a Letter of Intent to jointly develop a vaccine against the new coronavirus (known as 2019-nCoV). Under the collaboration, GeoVax will use its MVA-VLP vaccine platform and expertise to design and construct the vaccine candidate using genetic sequences from the ongoing coronavirus outbreak originating in Wuhan, China.
- GlobeNewswire
GeoVax Announces Reverse Stock Split
1:2000 Reverse Split Effective January 24, 2020;Ticker Symbol Changed to GOVXD for 20 Days ATLANTA, GA, Jan. 23, 2020 -- via NEWMEDIAWIRE – GeoVax Labs, Inc. (OTC: GOVX).
- GlobeNewswire
GeoVax to Present at World Vaccine & Immunotherapy Conference
Two Separate Presentations to Focus on the Company’s Infectious Disease Vaccines and Cancer Immunotherapy Programs ATLANTA, GA, Dec. 03, 2019 -- via NEWMEDIAWIRE -- GeoVax.
GlobeNewswireGeoVax Observes 2019 World AIDS Day
Developing Multiple Strategies Toward Ending the HIV/AIDS Epidemic ATLANTA, GA, Dec. 02, 2019 -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTC: GOVX), a biotechnology.
- GlobeNewswire
GeoVax to Present at Vaccines R&D Conference
Presentation to Focus on the Company’s MVA-VLP Platform for Safe and Effective Vaccines for Infectious Diseases and Cancer ATLANTA, GA, Nov. 14, 2019 -- via NEWMEDIAWIRE --.
- GlobeNewswire
GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure
The proposed clinical trial will enroll 20 HIV-infected adults who are on stable and effective antiretroviral therapy (ART). The therapeutic regimen to be tested involves a combination of vaccinations (DNA priming and MVA boosting), administration of broadly neutralizing antibodies (bNAbs) and a Toll-like receptor 9 (TLR9) agonist. GeoVax will provide its novel boost component (MVA62B) for use in the studies.
- Zacks Small Cap Research
GOVX: Third Quarter 2019 Results and Update
OTC:GOVX GeoVax Labs, Inc. (OTC:GOVX) filed its third quarter 2019 10-Q and issued the accompanying press release on November 7, 2019 providing an operational and financial update on the company’s performance. During the third quarter and to date GeoVax gave several presentations related to the Lassa fever, HIV and Marburg programs, issued additional shares to satisfy convertible preferred
- ACCESSWIRE
GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update
The Underlying Value of GeoVax, and the Promise of the Technology...A Comprehensive Review of GeoVax's Various Development Programs ATLANTA, GA / ACCESSWIRE / November 7, 2019 / GeoVax Labs, Inc. (OTCQB:GOVX), ...
- GlobeNewswire
GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV
On October 18, 2019, AGT announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for AGT’s lead HIV program, AGT103-T, a lentiviral vector-based gene therapy. Upon clearance by the FDA, this IND will allow AGT to initiate a Phase 1 clinical trial that will investigate the safety of AGT103-T in humans, measure key biomarkers, and explore surrogate markers of efficacy. AGT expects to begin recruiting patients for the Phase 1 study in January.
- GlobeNewswire
GeoVax Presenting at Upcoming October European Scientific Conferences
Unique Platform Continues to be Recognized for Distinct Benefits ATLANTA, GA, Oct. 15, 2019 -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company.
- GlobeNewswire
GeoVax CEO Comments on Recent Changes in Capital Structure
In recent weeks, we have seen a significant rise in the number of our common shares outstanding, which stands at 95,627,584 as of September 30, 2019. This increase is not due to new financings by GeoVax, but rather to the rapid liquidation of convertible preferred stock held by third party investors. Concurrent with this letter, we have filed a Form 8-K with the SEC giving further details. I encourage all shareholders to review this Form 8-K filing. As of September 30, there remain 3,054 shares of unconverted preferred stock ($3,053,782 stated value), which the investors may continue to convert into common stock over the coming weeks. As additional conversions occur, we will provide further updates via SEC filings in order to avoid selective disclosure to individual stockholders.
- Zacks Small Cap Research
GOVX: Second Quarter 2019 Results and Update
By John Vandermosten, CFA OTC:GOVX GeoVax Labs, Inc. (OTC:GOVX) filed its second quarter 2019 10-Q and issued the accompanying press release on August 14, 2019 providing an operational and financial update on the company’s performance. During the second quarter GeoVax announced a reverse stock split, presented data from several programs and participated in scientific
- ACCESSWIRE
Leveraging GeoVax's Vaccine Expertise To Take On Cancer
ATLANTA, GA / ACCESSWIRE / September 9, 2019 / GeoVax Labs, Inc. (GOVX), a biotechnology company developing human immunotherapies and vaccines has historically been associated with the development of vaccines against infectious diseases. The company is now leveraging the knowledge and expertise it has validated in infectious diseases and expanding the applicability of MVA-VLP into immuno-oncology (IO) with highly promising results. GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases and cancer using a novel patented Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) based vaccine platform.
- GlobeNewswire
GeoVax Announces Publication of Lassa Fever Vaccine Study Results
ATLANTA, GA, Sept. 04, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (GOVX), a biotechnology company developing human vaccines, today announced publication of its article entitled “A Single Dose of Modified Vaccinia Ankara Expressing Lassa Virus-like Particles Protects Mice from Lethal Intra-cerebral Virus Challenge.” The paper appears in the open access journal Pathogens published by MDPI, based in Basel, Switzerland, and can be viewed at https://www.mdpi.com/2076-0817/8/3/133. GeoVax’s Lassa fever vaccine (GEO-LM01) is based on the Company’s novel Modified Vaccinia Ankara (MVA) Virus-Like Particle (VLP) platform, which generates noninfectious VLPs in the individual being vaccinated.
- GlobeNewswire
GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress
ATLANTA, Aug. 14, 2019 -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human immunotherapies and vaccines, today announced its.
- GlobeNewswire
GeoVax Issues Shareholder Update Letter
Updates Provided on Financial Status and Development Programs ATLANTA, GA, Aug. 02, 2019 -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company.
- GlobeNewswire
GeoVax Addresses WHO Declaration of Ebola Outbreak as Global Public Health Emergency
ATLANTA, GA, July 30, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (GOVX), a biotechnology company developing human vaccines and immunotherapies, today responded to the World Health Organization’s (WHO) recent declaration of the Ebola outbreak in the Democratic Republic of the Congo (DRC) as a global public health emergency. The Company is offering its novel Ebola preventive vaccine (GEO-EM01), gratis, for public health use, contingent upon WHO or related agencies advancing the vaccine into human clinical evaluation. GeoVax believes its vaccine to be distinctly superior to the experimental vaccine currently in use in failing attempts to contain the epidemic. GeoVax has demonstrated that a single intramuscular (IM) dose of GEO-EM01 provided 100% protection in rhesus macaques challenged with a lethal dose of Ebola virus (EBOV).
- GlobeNewswire
GeoVax Announces 100% Protection Data from Marburg Virus Vaccine Study
Study Data Adds to Similar Efficacy Previously Reported for GeoVax’s Ebola and Lassa Fever Vaccines ATLANTA, GA, July 29, 2019 -- via NEWMEDIAWIRE – GeoVax Labs, Inc. (OTCQB:.
- GlobeNewswire
GeoVax Presents HIV Vaccine Study Data
Presentation Made at the 10th International AIDS Society Conference on HIV Science ATLANTA, GA, July 24, 2019 -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a.
